Shayan Fassih
A5012946663- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Diabetes and associated disorders
- SARS-CoV-2 detection and testing
- Global Cancer Incidence and Screening
- Hepatitis B Virus Studies
- Cardiovascular Disease and Adiposity
- Experimental Learning in Engineering
- Innovative Teaching Methods
- Cervical Cancer and HPV Research
- Single-cell and spatial transcriptomics
- COVID-19 epidemiological studies
- Inflammatory Biomarkers in Disease Prognosis
- Biomedical and Engineering Education
- vaccines and immunoinformatics approaches
- Biomarkers in Disease Mechanisms
- Long-Term Effects of COVID-19
University of Oxford
2021-2022
University of Worcester
2021
Oxford University Hospitals NHS Trust
2021
<h2>Summary</h2><h3>Background</h3> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. Serology considered key to population-level surveillance potentially individual-level risk assessment. However, immunoassay performance not been compared on large, identical sample sets. We aimed investigate the of four high-throughput commercial SARS-CoV-2 antibody immunoassays novel...
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying severity in an integrated comparison influenza sepsis versus healthy volunteers. identify signatures correlates host response. Hallmarks disease involved cells, their inflammatory mediators networks, including progenitor cells myeloid lymphocyte subsets, features the repertoire,...
Abstract The trajectories of acquired immunity to severe acute respiratory syndrome coronavirus 2 infection are not fully understood. We present a detailed longitudinal cohort study UK healthcare workers prior vaccination, presenting April-June 2020 with asymptomatic or symptomatic infection. Here we show highly variable range responses, some which (T cell interferon-gamma ELISpot, N-specific antibody) wane over time, while others (spike-specific antibody, B memory ELISpot) stable. use...
Summary Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete understanding potentially druggable immune mediators disease. To advance this, we present a comprehensive multi-omic blood atlas in patients with varying severity compare influenza, sepsis healthy volunteers. We identify signatures correlates host response. Hallmarks disease revealed cells, their inflammatory networks as potential therapeutic targets, including progenitor cells specific myeloid...